Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 4/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 0.79 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.79 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.74 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.74 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.74 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.74 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.74 |
| ▸ | BRAF | P15056 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29482205 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL7051381 | 0.96 | MAP2K1 (0.96) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL4861666 | 0.94 | MAP2K1 (1.00) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL4856675 | 0.93 | MAP2K1 (0.94) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL30022418 | 0.92 | MAP2K1 (0.85) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL22030445 | 0.92 | MAP2K1 (0.85) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL22029977 | 0.91 | MAP2K1 (0.84) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL22026444 | 0.91 | MAP2K1 (0.84) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL22028122 | 0.91 | MAP2K1 (0.84) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL26046795 | 0.90 | MAP2K1 (0.82) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | claimed |
| US-6972298-B2 | Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor | WARNER-LAMBERT COMPANY (US) | 2005-12-06 | — | — | US | claimed |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2005-08-11 | — | — | US | claimed |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2004-03-18 | — | — | US | claimed |
| CN-1446197-A | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER LAMBERT CO (US) | 2003-10-01 | — | — | CN | claimed |
| EP-1301472-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2003-04-16 | — | — | EP | claimed |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | BARAGI VIJAYKUMAR M (US) | 2003-03-20 | — | — | US | claimed |
| EP-1262176-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | WARNER-LAMBERT COMPANY (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2002006213-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-01-24 | — | — | WO | claimed |
| EP-3481822-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11311624-B2 | Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-26 | — | — | US | disclosed |
| US-10919877-B2 | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200164081-A1 | INHIBITORS OF MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR AND MEK/PI3K/mTOR BIOLOGICAL PATHWAYS AND METHODS FOR IMPROVING LYMPHATIC UPTAKE, BIOAVAILABILITY, AND SOLUBILITY OF THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-28 | — | — | US | disclosed |
| US-20190224207-A1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-25 | — | — | US | disclosed |
| US-20040006245-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | REWCASTLE GORDON WILLIAM (NZ) | 2004-01-08 | — | — | US | disclosed |
| WO-2003062191-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-1301472-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | BARAGI VIJAYKUMAR M (US) | 2003-03-20 | — | — | US | disclosed |
| EP-1262176-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | WARNER-LAMBERT COMPANY (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2002006213-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | CYP4X1, CYP2A7, CYP4B1 | MAP2K1 4341/4885MAP2K2 4268/4885PIM1 1919/4885 |
| US-11311624-B2 | Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds | MTOR, JAK2, JAK1 | MAP2K1 58/4885MAP2K2 49/4885PIM1 91/4885 |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | CYP4X1, ALOX5, HAAO | MAP2K1 4312/4885MAP2K2 4025/4885PIM1 2425/4885 |
| US-10919877-B2 | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same | MTOR, PIK3CA, MAPKAP1 | MAP2K1 100/4885MAP2K2 83/4885PIM1 145/4885 |
| US-20040006245-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | HCAR2, EGLN3, AADAC | MAP2K1 4692/4885MAP2K2 4611/4885PIM1 4391/4885 |
| US-20200164081-A1 | INHIBITORS OF MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR AND MEK/PI3K/mTOR BIOLOGICAL PATHWAYS AND METHODS FOR IMPROVING LYMPHATIC UPTAKE, BIOAVAILABILITY, AND SOLUBILITY OF THERAPEUTIC COMPOUNDS | MTOR, JAK2, JAK1 | MAP2K1 58/4885MAP2K2 49/4885PIM1 91/4885 |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | MMP8, SERPINB1, CXCR2 | MAP2K1 105/4885MAP2K2 89/4885PIM1 576/4885 |
| US-20190224207-A1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | MTOR, PIK3CA, MAPKAP1 | MAP2K1 100/4885MAP2K2 83/4885PIM1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.